Workflow
荣昌生物: 荣昌生物制药(烟台)股份有限公司关于续聘会计师事务所的公告
Zheng Quan Zhi Xing·2025-03-27 12:27

Core Viewpoint - The company intends to reappoint Ernst & Young Hua Ming as the A-share audit firm and Ernst & Young as the Hong Kong audit firm for the year 2025, highlighting their compliance with legal and ethical standards in previous audits [1][2][6]. Group 1: A-share Audit Firm Information - Ernst & Young Hua Ming was established in September 1992 and transitioned to a special partnership in August 2012, with its headquarters in Beijing [2]. - The firm reported a total audited business revenue of RMB 5.955 billion for 2023, with audit service revenue of RMB 5.585 billion and securities service revenue of RMB 2.438 billion [2]. - Ernst & Young Hua Ming has audited 137 A-share listed companies in 2023, generating a total fee of RMB 905 million [2]. Group 2: Audit Firm's Compliance and Performance - The firm has a strong investor protection capability, with a cumulative compensation limit exceeding RMB 200 million from its professional risk fund and insurance [3]. - Over the past three years, Ernst & Young Hua Ming has not faced any civil lawsuits or criminal penalties related to its auditing practices [3][5]. - The project partner, Yang Jing, has been a registered accountant since 2015 and has experience in auditing listed companies in the specialized equipment manufacturing and pharmaceutical manufacturing sectors [4]. Group 3: Hong Kong Audit Firm Information - Ernst & Young Hong Kong is a partnership firm providing audit, tax, and consulting services to numerous Hong Kong-listed companies, including financial institutions [5][6]. - The firm has been engaged by the company since 2019 to provide audit services for financial statements submitted to the Hong Kong Stock Exchange [6]. Group 4: Approval Process for Reappointment - The Audit Committee approved the reappointment of the audit firms during its meeting on March 27, 2025, citing their adherence to legal and ethical standards [6][7]. - The Board of Directors also approved the reappointment and agreed to submit the proposal for shareholder approval [7].